CBW 511
Alternative Names: CBW-511Latest Information Update: 11 Nov 2022
At a glance
- Originator Caliway Biopharmaceuticals
- Class Hepatoprotectants; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic fatty liver disease; Obesity
Most Recent Events
- 03 Nov 2022 Discontinued - Phase-II for Obesity in Taiwan (PO) before November 2022 (Caliway Biopharmaceuticals pipeline, November 2022)
- 03 Nov 2022 Discontinued - Preclinical for Non-alcoholic fatty liver disease in Taiwan (PO) before November 2022 (Caliway Biopharmaceuticals pipeline, November 2022)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in Taiwan (PO)